EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

Giulia Notini iD, Giampaolo Bianchini iD, José Manuel Pérez-García, Javier Cortés iD

PLOS Medicine · 30.01.2026 · 23 (1) · e1004930

DOI: 10.1371/journal.pmed.1004930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 30.01.2026. Verfasst von Giulia Notini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Immunoconjugates, Breast Neoplasms, Antineoplastic Agents, Immunological, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesBreast NeoplasmsAntineoplastic Agents, ImmunologicalAntineoplastic AgentsHumansFemaleClinical Trials as Topic

Substanzen

ImmunoconjugatesAntineoplastic Agents, ImmunologicalAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
  • School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
  • International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
  • Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
  • IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain.
  • Oncology Department, Hospital Universitario Torrejón, Ribera Salud Group, Madrid, Spain.

ORCID-Profile: Giulia Notini, Giampaolo Bianchini, Javier Cortés

Zitieren

APA

Notini, G., Bianchini, G., Pérez-García, J. M., & Cortés, J. (2026). Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy. PLOS Medicine, 23(1), e1004930. https://doi.org/10.1371/journal.pmed.1004930

Vancouver

Notini G, Bianchini G, Pérez-García JM, Cortés J. Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy. PLOS Medicine. 2026;23(1):e1004930. doi:10.1371/journal.pmed.1004930

BibTeX
@article{Notini2026,
  author = {Notini, Giulia and Bianchini, Giampaolo and Pérez-García, José Manuel and Cortés, Javier},
  title = {Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {e1004930},
  doi = {10.1371/journal.pmed.1004930}
}
Kostenlos starten →